Heron Therapeutics Management
Management criteria checks 2/4
Heron Therapeutics' CEO is Craig Collard, appointed in Apr 2023, has a tenure of 2.08 years. total yearly compensation is $3.40M, comprised of 19.7% salary and 80.3% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth €798.65K. The average tenure of the management team and the board of directors is 1.8 years and 3.7 years respectively.
Key information
Craig Collard
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 19.72% |
| CEO tenure | 2.1yrs |
| CEO ownership | 0.3% |
| Management average tenure | 1.8yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$8m |
| Dec 31 2024 | US$3m | US$670k | -US$14m |
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$48m |
| Mar 31 2024 | n/a | n/a | -US$81m |
| Dec 31 2023 | US$11m | US$488k | -US$111m |
Compensation vs Market: Craig's total compensation ($USD3.40M) is above average for companies of similar size in the German market ($USD963.69K).
Compensation vs Earnings: Craig's compensation has been consistent with company performance over the past year.
CEO
Craig Collard (58 yo)
2.1yrs
Tenure
US$3,395,492
Compensation
Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.1yrs | US$3.40m | 0.28% € 798.6k | |
| Executive VP & CFO | 1.9yrs | US$1.42m | 0.089% € 255.3k | |
| Executive VP & Chief Development Officer | 1.9yrs | US$1.54m | 0.080% € 229.8k | |
| Executive VP & COO | less than a year | no data | no data | |
| Vice President of Marketing | 1.8yrs | no data | no data | |
| Senior Vice President of Manufacturing & Supply | less than a year | no data | no data | |
| Senior Vice President of Oncology Care Franchise & Commercial Operations | 2.3yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Senior Vice President of Medical Affairs Strategy & Engagement | 1.3yrs | no data | no data | |
| Executive Director | no data | no data | no data |
1.8yrs
Average Tenure
55yo
Average Age
Experienced Management: AXD2's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.40m | 0.28% € 798.6k | |
| Independent Director | 11.3yrs | US$160.00k | 0.043% € 123.4k | |
| Independent Director | 8.9yrs | US$155.63k | 0.043% € 124.1k | |
| Independent Director | less than a year | US$323.91k | 0.0015% € 4.4k | |
| Independent Director | 3.7yrs | US$153.75k | 0.045% € 128.4k | |
| Independent Chairman | 2.3yrs | US$166.25k | 0.022% € 61.7k | |
| Independent Director | 3.7yrs | US$152.50k | 0.045% € 128.4k |
3.7yrs
Average Tenure
57yo
Average Age
Experienced Board: AXD2's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 06:27 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Heron Therapeutics, Inc. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Jonathan Aschoff | Brean Capital |
| Jonathan Aschoff | B. Riley Wealth |